Get Latest updates :
  • Home
  • Register
  • Log In
  • Contact Us
News and Updates around World
  • Automotive
  • Business
  • Education
  • Entertainment
  • Health & Fitness
  • Real Estate
  • Sports
  • Technology
  • Travel
  • World News
  • Automotive
  • Business
  • Education
  • Entertainment
  • Health & Fitness
  • Real Estate
  • Sports
  • Technology
  • Travel
  • World News
No Result
View All Result
News and Updates around World
No Result
View All Result
Home Business

Bharat Biotech asked to submit complete phase 2 data of its COVID-19 vaccine before phase 3 trial

Bharat Biotech asked to submit complete phase 2 data of its COVID-19 vaccine before phase 3 trial
Share on FacebookShare on Twitter

Synopsis

According to officials, the Hyderabad-based vaccine maker applied to the Drugs Controller General of India (DCGI) on October 2, seeking its permission to conduct phase-3 randomised double-blind placebo-controlled multicentre trial of its COVID-19 vaccine candidate.

Reuters
According to sources, the phase-2 trial of the Covaxin is going on and the second dose is yet to be given to volunteers at some sites.

NEW DELHI:
Bharat
Biotech, which had sought DCGI’s nod for conducting phase-3 clinical trials of its COVID-19 vaccine candidate, has been asked to submit complete safety and immunogenicity data of the ongoing phase-2 trial, besides providing some clarifications, before proceeding for the next stage.

The vaccine candidate — ‘Covaxin’ — is being indigenously developed by the
Bharat
Biotech in collaboration with the Indian Council of Medical Research (ICMR).

According to officials, the Hyderabad-based vaccine maker applied to the Drugs Controller General of India (DCGI) on October 2, seeking its permission to conduct phase-3 randomised double-blind placebo-controlled multicentre trial of its COVID-19 vaccine candidate.

The firm in its application said that the study would cover 28,500 subjects aged 18 years and above and would be conducted in 19 sites — including Delhi, Mumbai, Patna and Lucknow — across 10 states.

According to sources, the phase-2 trial of the Covaxin is going on and the second dose is yet to be given to volunteers at some sites.

“The company presented phase-3 clinical trial protocol along with interim data of phase 1 and 2 clinical trials,” an official said.

The subject expert committee (SEC) at the Central Drugs Standard Control Organisation(CDSCO) deliberated on the application on October 5.

“After a detailed deliberation, the committee opined that the design of the phase-3 study is in principle satisfactory except for clarification on definition of asymptomatic, etc.

“However, the study should be initiated with appropriate dose identified from the phase-2 safety and immunogenicity data. Accordingly, the firm should submit safety and immunogenicity data from phase-2 trial for consideration,” the panel said in its recommendations.

The SEC during its discussion also observed that the vaccine was well-tolerated in all dose groups and no serious adverse events have been reported so far, a source said.

The most common adverse event was pain at the injection site, which resolved transiently, the source said.

The phase-3 clinical trial application proposed a dose of 0.5 ml on day 0 and 28, sources said.

Besides,
Bharat
Biotech, indigenously developed vaccine candidate by Zydus Cadila Ltd is in the phase 2 of the human clinical trials.

The Pune-based Serum Institute of India, which has partnered with AstraZeneca for manufacturing the Oxford COVID-19 vaccine candidate, is also conducting Phase 2 and 3 human clinical trials of the candidate in India.

(Catch all the Business News, Breaking News Events and Latest News Updates on The Economic Times.)

Download The Economic Times News App to get Daily Market Updates & Live Business News.

Also Read

1 Comment on this Story

Baiju Bhaskaran3 hours ago

If the Phase 2 results are OK,then the government should not wait for phase 3 results. Instead they should start vaccinating small groups of people like healthcare workers, police, paramilitary and military personnel. After complete result of phase 3 trials the remaining population can be vaccinated.

Read More

ShareTweetPin

Related Posts

Must Have Items for Your Cleaning Business
Business

Must Have Items for Your Cleaning Business

by vixus sky
April 19, 2022
‘Travesty of justice’, Muslim Personal Law Board moves SC against HC verdict on hijab
Business

‘Travesty of justice’, Muslim Personal Law Board moves SC against HC verdict on hijab

by Benjamin Obescu
March 29, 2022
CM Yogi Adityanath, Akhilesh Yadav take oath as members of UP Assembly
Business

CM Yogi Adityanath, Akhilesh Yadav take oath as members of UP Assembly

by Benjamin Obescu
March 29, 2022
Shanghai starts China’s biggest COVID-19 lockdown in 2 years
Business

Shanghai starts China’s biggest COVID-19 lockdown in 2 years

by Benjamin Obescu
March 29, 2022
BKU leader Rakesh Tikait receives ‘death’ threat; complaint filed
Business

BKU leader Rakesh Tikait receives ‘death’ threat; complaint filed

by Benjamin Obescu
March 29, 2022

Premium Content

‘The View’ Co-Hosts Call Out Olivia Jade For Not Recognizing White Privilege: She’s An ‘Entitled Brat’

‘The View’ Co-Hosts Call Out Olivia Jade For Not Recognizing White Privilege: She’s An ‘Entitled Brat’

December 17, 2020
IPL 2022, LSG vs GT LIVE Updates: Lucknow Super Giants Face Gujarat Titans In Top-Of-The-Table Clash

IPL 2022, LSG vs GT LIVE Updates: Lucknow Super Giants Face Gujarat Titans In Top-Of-The-Table Clash

May 10, 2022

NYC to allow Central Park ice rinks to stay open for rest of season

February 22, 2021

Browse by Category

  • Automotive
  • Business
  • Education
  • Entertainment
  • Health & Fitness
  • Real Estate
  • Sports
  • Technology
  • Travel
  • World News

© 2020 Nicardo.com

No Result
View All Result
  • Home
  • Entertainment
  • Sports
  • World News
  • Technology
  • Real Estate
  • Education
  • Travel
  • Health & Fitness
  • Automotive

© 2020 Nicardo.com